Management of vitamin D deficiency in young women with 1-year follow up

C. Perdrix[1], O. Large[2], R. Fauché[1], C. Dupraz[1], M. F. LeGoaziou[1*]

[1]Collège des Enseignants Généralistes, Université Claude Bernard Lyon 1, Lyon, France;
[*]Corresponding Author: mf.legoaziou@medsyn.fr
[2]Sainte Foy les Lyon, Lyon, France

ABSTRACT

Vitamin D deficiency is very frequently observed among young women. This study reports the follow up of 68 women over a period of 1 year. The objective of this study was to observe doses of vitamin D can correct and preserve blood levels of vitamin D near 75 nmol/L. It was found that large amounts of vitamin D are needed to correct and then maintain vitamin D blood levels (≥530,000 units), particularly in veiled women (~720,000 units). Parathyroid hormone (PTH) levels decreased as blood levels of vitamin D increased. Quality of life measured with the SF12® Health Survey questionnaire, improved when the patients' vitamin D deficiencies were corrected. This work highlights the need for the development of guidelines to treat and correct vitamin D deficiency for the long term in young adult women.

Keywords: Hypovitaminosis D; Treatment; Adult Women; Follow up

1. INTRODUCTION

In our prior 2008 study [1] examining young women who were found to have severe vitamin D deficiencies by their general practitioners (GPs), we identified known risk factors for vitamin D deficiency, such as wearing clothes that leave little or no skin exposed, having a high body mass index (BMI), having a dark skin phototype, practicing indoor sports exclusively or no sports at all, and social insecurity. Several studies reported major improvements in highly deficient patients experiencing pain or poor health outcomes before treatment, when their deficiency was corrected [2-4].

We followed a group of women who had been recruited for the VESTAL study with the aim of bringing their vitamin D levels to ≥75 nmol/L, and maintaining improved levels for 1 year. We also analysed how serum levels of vitamin D are related to pain and the quality of life.

This study was a pragmatic observation study that consisted of following a cohort of deficient women originating from the VESTAL study for a period of 1 year. For this study, women were followed by their GP as part of the usual visits. This study fulfils the criteria for a non-interventional study as defined by articles L.1121-1 and R.1121-2 of the public health code.

2. METHOD

2.1. Population Studied

The vitamin D deficient women in the study were between 19 and 49 years old. They agreed to be followed for a year.

The criteria for exclusion were: an on-going pregnancy; a psychiatric pathology that could seriously interfere with her ability to understand what she was consenting to; or any pathology that developed following enrolment in the study that could interfere with phosphocalcic metabolism (e.g., liver deficiency, kidney deficiency, absorption deficiency, skin disease).

Women were followed as part of their routine visits to their GPs. The deficiency was treated with vitamin D supplementation, and a biological and clinical assessment was carried out every 3 months for 1 year. GPs agreed to communicate the data necessary to carry out this observational study. The patients were informed orally that data concerning the correction of their hypovitaminosis would be disseminated anonymously, and that a visit every 3 months would be required to ensure that their serum levels of vitamin D were normal. A refusal of these conditions led to the rejection from the study.

2.2. Parameters Studied

2.2.1. Vitamin D and PTH

The BIOMIS® and DIASORIN® laboratories elected to continue the collaboration started for the VESTAL

study. The treatments were free for the patients. 25(OH) vitamin D was measured by the chemiluminescence analyzer of DIASORIN, the LIAISON® 25OH Vitamin D analyser which have sensitivity at 0.970 and specificity at 0.987. Vitamin D2 + D3 were to be taken for 1 month following the last oral intake of vitamin D. This supplementation regime was repeated every 3 months for 1 year. Normal values fell in the range of 75 - 200 nmol/L. The toxic threshold was set at 250 nmol/L. A single dose of PTH was administered upon inclusion into the VESTAL study. To limit costs, PTH was only measured at the end of the study for patients who had an abnormal PTH level at the start of the study. PTH levels in the range of 15 - 65 ng/L were considered normal.

2.2.2. Others Data

At the beginning and the end, patients filled out an SF12® Health Survey questionnaire on quality of life. This questionnaire measure the variation for physical components summary (PCS) and the mental components summary (MCS) [5]. Pain evolution and fatigue data were collected at each visit, using 0 - 10 scales (with 10 being maximum fatigue and maximum pain). Supplement doses taken by the patients were recorded. And, at the end of the study, the patients were asked to assess their health. All of these data were collected in an anonymous grid that was filled out by the GPs. Advice concerning D3 supplementation in relation to patient vitamin D levels, based on the literature [6] was provided to the GPs as follows:

- when vitamin D is <30 nmol/L: prescribe 100,000 UI of vitamin D3 every 15 days for 2 months, corresponding to 400,000 UI in 2 months.
- when vitamin D is between 30 and 50 nmol/L: prescribe 100,000 UI of vitamin D3 every month for 2 months, corresponding to 200,000 UI in 2 months.
- when vitamin D is between 50 and 75 nmol/L: prescribe a single dose of 100,000 UI, corresponding to 100,000 UI in 2 months.
- when vitamin D is >75 nmol/L: no supplementation is needed.

Each GP was free to follow those recommendations or to prescribe the supplementation doses according to his or her own established practices. In any case, the patients were informed of the dosage they were prescribed.

2.2.3. Data Analysis

The data were analysed using software SAS Institute software (Cary, NC). The patients were described based on their main characteristics expressed as means, medians, and standard deviations for the quantitative variables, and as frequency and percent for qualitative variables. The data were rendered anonymous and the study followed the norm MR001 of the CNIL (Commision Na-

tional Informatique et Liberté). This work was not financed beyond the free supplements provided by DIASORIN and BIOMNIS. The authors declare no conflicts of interest.

3. RESULTS

3.1. Subjects

Among 186 women initially included in the study, 113 participated up to the first control time point and 65 were tested three times during the year Among the 121 missing women at the end of the year, 15 had become pregnant, 6 moved residence, 15 never collected their first treatment, 7 had a serious illness independent of their hypovitaminosis, 4 refused to continue the study, 2 reached the age limit, 6 were lost due to their GP leaving the study together, 18 were considered lost as their GPs did not hear from them despite several reminders, and 48 participated to only one or two controls and they were declared non-observable. The cohort of 65 women who took at least 3 dosages and who filled the questionnaire of end of study were followed-up. The number of veiled and non-veiled women varied similarly throughout the study. The mean age of the group was 36.7 years old and 18% received benefits from Couverture Médicale Universelle (CMU), a free medical coverage for very low income populations.

3.2. Evolution of Serum Levels of Vitamin D

At visit 1, 2, 3 and 4, veiled women had respectively a mean of 20.27 ± 12.70, 68.07 ± 28.57, 63.07 ± 18.51 and 68.13 ± 27.80 nmol/L in comparison with non-veiled women who had 33.76 ± 17.1; 85.58 ± 28.57; 69.88 ± 29.60, 76.86 ± 37.90 nmol/L (**Figure 1**).

Among women who presented a level ≥ 75 nmol/L and who therefore were not prescribed a new treatment dose, serum levels of vitamin D evolved in a saw-like fashion (**Figures 2** and **3**).

The serum levels of vitamin came to exceed 200 nmol/L in 4 patients, but never surpassed 250 nmol/L.

3.3. Quantity of Vitamin D Consumed

Over a year, veiled woman were given a mean cumulative dose of 720,000 UI of vitamin D, while unveiled women consumed 530,000 UI of vitamin D. Hence, wearing covering clothes was associated with prescription of larger doses of vitamin D. Regardless, the serum levels of vitamin D remained lower in veiled women (**Figure 4**).

3.4. PTH

PTH levels evolved in a manner that was opposite to the pattern observed with vitamin D (**Figure 5**). The

Figure 1. Evolution of vitamin D levels following inclusion in the study in veiled patients versus non-veiled patients.


Figure 2. Evolution of vitamin D levels in women who not provided with a dose of vitamin D following their first doctor's visit.


Figure 3. Evolution of vitamin D levels in women who were provided with a single dose of vitamin D following their first doctor's visit.

(mean PTH level was maximal (58 ± 21.6 ng/L) at the first measurement (V1), when the mean vitamin D level was at its lowest (30.4 ± 18.3 nmol/L). Conversely, the mean PTH level was at its lowest (52.6 ± 22.9 ng/L) at the second measurement (V2), when the mean vitamin D level was at its highest (82.1 ± 39.8 nmol/L).

3.5. Pains and Asthenia

No difference was observed for these two items. At the first time, the mean of the pain and the asthenia was at 2.5. After the first correction, this value decreased to 2 but after, it returned to 2.5.

3.6. Quality of Life

No significative differences in quality of life were observed after correction, perhaps due to there being an insufficient number of subjects to reveal such differences. At the beginning mean for PCS was at 47.8 and for MCS at 41.3. At the end of the year values were respectively 48.2 and 41.8. The p values with the Wilcoxon test were 0.91 for the PCS and 0.94 for the MCS. However, an improvement of the quality of life correlated to higher serum vitamin D level was observed.


Figure 4. Mean number of vials of vitamin D taken by veiled and non-veiled patients.


Figure 5. Evolution of vitamin D and PTH levels.

4. DISCUSSION

4.1. Limitation of the Study

A large portion of patients was lost during the course of the study. A comparison between women who left the study (N = 121) and those who completed it (N = 65) did not reveal differences in age, phototype, type of clothes worn, or enrolment in the CMU program. Mean vitamin D level, mean PTH level, and initial level of pain also did not differ between women who completed the study versus those who did not. Therefore, the dropping out of patients did not appear to alter the overall pattern of result. Many patients mentioned that they felt better and did not feel the necessity to consult their GP again.

The difficulty we encountered in terms of following patients in primary care is one that was also met by prior researchers, including Vieth and Levis in their respective studies. Indeed, Vieth lost half of his cohort of patients in a 5 months-long study [7] and Levis lost 53% of his patients between winter and summer [8].

4.2. Correction of the Deficiency and Preservation of the Level

The quantity of vitamin D prescribed to correct deficiencies and maintain serum vitamin D levels above 75 nmol/L was very high in our cohort, and vitamin D supplementation was even higher in veiled women than non-veiled women. As described in the literature, keeping vitamin D levels in the normal range appears to require not waiting to intervene until levels fall below 75 nmol/L For example, in a study performed in the United Arab Emirates, Saadi *et al.* reported a high prevalence of vitamin D deficiency (mean level of 19 nmol/L at inclusion) and also confirmed the importance of vitamin D supplementation in patients that are rarely exposed to the sun [9].

In a double-blind study using two supplementation dosages [25 μg/day (= 1000 UI/day) or 100 μg/day (4000 UI/day)] and an initial mean level of vitamin D higher than that in our study (40.7 vs. 30.4 nmol/L), Vieth *et al.* concluded that a daily intake of 1000 UI/day was not sufficient to ensure attainment of levels ≥75 nmol/L in most patients, whereas an intake of 4000 UI/day was sufficient [4].

Aloia *et al.* also studied the dose of vitamin D necessary to reach serum levels of at least 75 nmol/L. A protocol was set up and analysed over a 6-month period in a cohort of 138 patients. Based on their results, the authors recommended an intake of 95 μg/day (3800 UI/day) for patients with a serum vitamin D level of 55 nmol/L or higher, and an intake of 125 μg/day (5000 UI/day) for patients with a level lower than 55 nmol/L [10].

Holick *et al.* proposed that hypovitaminosis D be treated with 50,000 UI/week for 8 weeks to reach levels in the range of 75 - 125 nmol/L. Following a second measurement, it is then possible to give a dose of 50,000 UI every 2 weeks thereafter [6]. These studies show the diversity of possible therapeutic corrections and the high quantity of supplements required to treat serious deficiencies. The quantities consumed by our patients were similar to these proposed dosage regimens. Implementation of ~100,000 UI per week doses, offers the advantage of producing effects that are more readily observable.

4.3. Innocuity of Vitamin D

No vitamin D toxicity was found despite some cases of high serum levels. A bibliographic review by Vieth showed that hypercalcemia is always accompanied by serum vitamin D levels higher than 220 nmol/L [7-11].

Heaney *et al.* supplemented patients who presented with serum levels close to 70 nmol/L for 20 weeks at dosages of 5500 and 11,000 UI/day. None presented with hypercalcemia, however a patient had a serum vitamin D concentration of 220 nmol/L [12].

Indeed, in a literature review, Hathcock *et al.* assessed the upper limit of vitamin D intake that can be tolerated. The absence of toxicity in trials conducted on healthy men led them to propose an upper limit tolerance of 250 μg/day (10,000 UI/day) [13].

Moreover, Vieth has indicated that sun exposure can lead to levels of vitamin D higher than 200 nmol/L without triggering hypercalcemia [7].

According to Holick the rare cases of hypervitaminosis that have been observed were the consequence of accidental massive ingestion of vitamin D; doses of ~50,000 UI/day appeared to be necessary to increase a patient's serum vitamin D level to 374 nmol/L. Doses of 10,000 nmol/L do not appear to be toxic [6].

Hathcock *et al.* have confirmed that toxicity is linked to accidental ingestion, an interaction between medicines (e.g., mixture with a thiazidic compound), or an unfavourable biological background (e.g., kidney insufficiency) [13].

4.4. Evolution of PTH

Our study confirmed that serum level of vitamin D is inversely associated with PTH level. Indeed, PTH levels diminish when vitamin D levels increase. This inverse relation is widely acknowledged in the literature [14].

In a study aimed at testing various supplementation protocols, Heaney *et al.* showed that it is important to treat a hypovitaminosis to reduce a secondary hyperparathyroidism. They found that variation of PTH levels consistently correlated inversely with variation of vitamin D levels (p < 0.01) [15].

Lips *et al.* made a similar observation in a study car-

ried out with 7564 patients in 25 countries. After treatment with 400 - 600 UI/day for 6 months, PTH levels decreased significantly depending upon the patient's level of vitamin D at inclusion. When vitamin D levels were <25 nmol/L, 25 - 50 nmol/L, or over 50 nmol/L, PTH levels decreases by 0.8, 0.5, and 0.2 pmol/L, respectively (p < 0.001). Decreases in PTH levels are all the more important when initial serum levels of vitamin D are low [16].

4.5. Improvement of Clinical Signs

We did not observe a significant improvement of clinical signs (asthenia and pain), however a trend was observed. Indeed, the analysis of the patients' answers to the SF12 questionnaire showed that patients who experienced stronger increases in vitamin D levels between V1 and V3 also had improvements in their physical summary score (PSS). A similar association was not found with the mental summary score (MSC), indicating that the physical improvement observed was not attributable to improvement of an underlying psychiatric disorder.

The symptom of tiredness in veiled patients generally decreased over the course of the study; however pain did not decrease. The persistence of pain might be due to that doses of vitamin D administered being too low to maintain constant levels throughout the year. Non-regularly supplemented high risk women saw their serum levels diminish. Over the course of a randomised study, Vieth *et al.* showed an effect of vitamin D3 intake on the wellbeing of patients, with a dose of 4000 UI/day being more efficient than a dose of 600 UI/day for improvement of well-being [4].

Guidelines currently appear to correct deficiency and maintain optimal vitamin level with high doses 6000 UI/day during 8 weeks to correct and 600 to 2000 UI/day to maintain according to risk factors [17].

5. CONCLUSION

This study of young women deficient in vitamin D who consulted their GPs underscores the difficulty involved with correcting hypovitaminosis D and maintaining long-term circulating levels of vitamin D within the normal range. Vitamin D supplementation must be delivered at high doses to correct severe deficiencies. Continuity of supplementation seems to be particularly important for patients presenting with risk factors. Such low sun exposure, obesity, dark phototype as hypovitaminosis is adequately corrected, PTH levels are reduced, fatigue may diminish, and the quality of life may improve. In the absence of a sufficient intake of vitamin D through food or sufficient exposure to the sun, regular vitamin D supplementation is necessary. In the long term, it will be of interest to assess the gains in general health and health care costs associated with delivery of vitamin D supplementation. Currently guidelines appear for correction and supplementation adapted to risk factors.

6. ACKNOWLEDGEMENTS

REFERENCES

[1] Le Goaziou, M.F., Contardo, G., Dupraz, C., Martin, A., Laville, M. and Schott-Pethelaz, A.M. (2011) Risk factors for vitamin D deficiency in women aged 20-50 years consulting in general practice: A cross-sectional study. *European Journal of General Practice*, **17**, 146-152.

[2] De Torrente de la Jara, G., Pecoud, A. and Favrat, B. (2006) Female asylum seekers with musculoskeletal pain: The importance of diagnosis and treatment of hypovitaminosis D. *BMC Family Practice*, **7**, 4. doi:10.1186/1471-2296-7-4

[3] Turner, M.K., Hooten, W.M., Schmidt, J.E., Kerkvliet, J.L., Townsend, C.O. and Bruce, B.K. (2008) Prevalence and clinical correlates of vitamin D inadequacy among patients with chronic pain. *Pain Medicine*, **9**, 979-984. doi:10.1111/j.1526-4637.2008.00415.x

[4] Vieth, R., Kimball, S., Hu, A. and Walfish, P.G. (2004) Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. *Nutrition Journal*, **3**, 8. doi:10.1186/1475-2891-3-8

[5] Gandek, B., Ware, J.E., Aaronson, N.K., Alonso, J., Apolone, G., Bjorner, J., Brazier, J., Bullinger, M., Fukuhara, S., Kaasa, S., Leplège, A. and Sullivan, A. (1998) Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: Results from the IQOLA Project. *International Quality of Life Assessment. Journal of Clinical Epidemiology*, **51**, 1149-1158. doi:10.1016/S0895-4356(98)00106-1

[6] Holick, M.F. (2007) Vitamin D deficiency. *New England Journal of Medicine*, **357**, 266-281.

[7] Vieth, R., Chan, P.C. and MacFarlane, G.D. (2001) Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *American Journal of Clinical Nutrition*, **73**, 288-294.

[8] Levis, S., Gomez, A., Jimenez, C., Veras, L., Ma, F., Lai, S., Hollis, B. and Roos, B.A. (2005) Vitamin D deficiency and seasonal variation in an adult South Florida population. *Journal of Clinical Endocrinology & Metabolism*, **90**, 1557-1562. doi:10.1210/jc.2004-0746

[9] Saadi, H.F., Dawodu, A., Afandi, B.O., Zayed, R., Benedict, S. and Nagelkerke, N. (2007) Efficacy of daily and monthly high-dose calciferol in vitamin D-deficient nulliparous and lactating women. *American Journal of Clinical Nutrition*, **85**, 1565-1571.

[10] Aloia, J.F., Patel, M., Dimaano, R., Li-Ng, M., Talwar, S.A., Mikhail, M., Pollack, S. and Yeh, J.K. (2008) Vitamin D intake to attain a desired serum 25-hydroxyvi-

tamin D concentration. *American Journal of Clinical Nutrition*, **87**, 1952-1958.

[11] Vieth, R. (1999) Vitamin D supplementation, 25-hydroxy-vitamin D concentrations, and safety. *American Journal of Clinical Nutrition*, **69**, 842-856.

[12] Heaney, R.P. (2008) Vitamin D: Criteria for safety and efficacy. *Nutrition Reviews*, **66**, S178-S181. doi:10.1111/j.1753-4887.2008.00102.x

[13] Hathcock, J.N., Shao, A., Vieth, R. and Heaney, R. (2007) Risk assessment for vitamin D. *American Journal of Clinical Nutrition*, **85**, 6-18.

[14] Aloia, J.F., Talwar, S.A., Pollack, S., Feuerman, M. and Yeh, J.K. (2006) Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. *American Journal of Clinical Nutrition*, **84**, 602-609.

[15] Heaney, R.P., Davies, K.M., Chen, T.C., Holick, M.F. and Barger-Lux, M.J. (2003) Human serum 25-hydroxy-cholecalciferol response to extended oral dosing with cholecalciferol. *American Journal of Clinical Nutrition*, **77**, 204-210.

[16] Lips, P., Duong, T., Oleksik, A., Black, D., Cummings, S., Cox, D. and Nickelsen, T. (2001) A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. *Journal of Clinical Endocrinology & Metabolism*, **86**, 1212-1221. doi:10.1210/jc.86.3.1212

[17] Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., Murad, M.H. and Weaver, C.M. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism*, **96**, 1911-1930. http://dx.doi.org/10.1210/jc.2011-0385